STOK Stoke Therapeutics, Inc.
$27.76
Stoke Therapeutics, Inc. (STOK) Earnings News
Earnings press releases, previews and reviews for Stoke Therapeutics, Inc. (STOK), newest first. Our most recent is review: Stoke Therapeutics Misses on Launch-Driven Spending, but FDA Endpoint Deal Strengthens the Zorevunersen Case as Cash Runway Tightens.
Friday
October 30, 2026
7:39 AM ET
Stoke Therapeutics Misses on Launch-Driven Spending, but FDA Endpoint Deal Strengthens the Zorevunersen Case as Cash Runway Tightens
Earnings Whispers · Review
Thursday
October 29, 2026
4:01 PM ET
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Thursday
October 22, 2026
10:40 AM ET
Stoke's FDA Pre-NDA Outcome, Not Its Quarterly Loss, Is the Real Test for Shareholders
Earnings Whispers · Preview
Thursday
October 22, 2026
8:00 AM ET
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Monday
August 3, 2026
4:01 PM ET
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Monday
July 27, 2026
4:01 PM ET
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates